Two-year pemafibrate treatment reduced median liver stiffness by 0.54 kPa from 3.05 to 2.52 kPa in MASLD patients with hypertriglyceridemia, indicating fibrosis improvement (P < 0.001).
Observational (n=25)
No
Does pemafibrate improve liver fibrosis in patients with MASLD and hypertriglyceridemia?
Pemafibrate demonstrates potential hepatoprotective and antifibrotic effects in patients with MASLD and hypertriglyceridemia, independent of weight loss.
Effect estimate: -0.54 kPa (Hodges–Lehmann estimate) (95% CI -0.86 to -0.31 kPa)
Absolute Event Rate: 2.52% vs 3.05%
p-value: p=<0.001
Two-year pemafibrate treatment significantly improved liver stiffness and hepatic parameters independent of weight loss or fat reduction, indicating potential antifibrotic mechanisms. These real-world findings support the hepatoprotective role of pemafibrate and warrant validation in prospective trials.
Noritake et al. (Sun,) conducted a observational in Metabolic dysfunction–associated steatotic liver disease (MASLD) and hypertriglyceridemia (n=25). Pemafibrate vs. None (single-arm observational study) was evaluated on Change in magnetic resonance elastography-derived liver stiffness measurement (MRE-LSM) at 2 years (-0.54 kPa (Hodges–Lehmann estimate), 95% CI -0.86 to -0.31 kPa, p=<0.001). Two-year pemafibrate treatment reduced median liver stiffness by 0.54 kPa from 3.05 to 2.52 kPa in MASLD patients with hypertriglyceridemia, indicating fibrosis improvement (P < 0.001).